Werewolf Therapeutics, Inc. (HOWL)
HOWLNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.00
-0.0100 (-0.99%) today
At the close, Nov 10, 4:00 PM ET. After hours $1.00 +3.09%
- Market cap
- $47.14m
- P/E
- –
- EPS, last 4 quarters
- $-0.7600
- Dividend yield
- –
- Day range
- $0.9700 to $1.01
- 52-week range
- $0.2700 to $1.21
- Average volume
- 560.4k
- Previous close
- $1.01
Earnings
Next report
Sep 2025
+7.7%
Dec 2025
+41.2%
Mar 2026
+12.5%
Jun 2026
+128.6%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | $21.00m |
| Gross profit | – | – | – | $21.00m |
| Operating income | -$15.73m | -$9.42m | -$13.27m | $7.16m |
| Net income | -$16.37m | -$8.38m | -$13.53m | $3.67m |
News
8 latest- Werewolf Therapeutics, Inc. Announces Clinical Data for WTX-124 and WTX-330Fintel · 1 day ago
- Roche Gets FDA Approval for Enspryng in Thyroid Eye DiseaseZacks · Oct 16, 2026
- KRYS Reports Positive Early Data for KB113 in Gorlin SyndromeZacks · Oct 16, 2026
- Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's WhyZacks · Oct 13, 2026
- TGTX Stock Rises 60% in 6 Months: Here's What You Should KnowZacks · Oct 13, 2026
- Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver DiseasesZacks · Oct 13, 2026
- New Strong Buy Stocks for October 9thZacks · Oct 9, 2026
- HALO Expands ENHANZE Collaboration & Licensing Deal With ARGXZacks · Oct 7, 2026
The company
Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. Werewolf Therapeutics has designed conditionally activated INDUKINE molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf's INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Werewolf Therapeutics' clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 and Interleukin-12 INDUKINE molecules, respectively, for the treatment of solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- werewolftx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.